董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Rocklage | 男 | Director and Chairman | 63 | 12.30万美元 | 未持股 | 2018-04-27 |
| Theodore R. Schroeder | 男 | Director | 63 | 10.80万美元 | 未持股 | 2018-04-27 |
| Timothy R. Franson | 男 | Director | 66 | 9.92万美元 | 未持股 | 2018-04-27 |
| Daniel D. Burgess | 男 | Director | 56 | 10.92万美元 | 未持股 | 2018-04-27 |
| Jeffrey Stein | 男 | Director,President and Chief Executive Officer | 63 | 182.38万美元 | 未持股 | 2018-04-27 |
| Chrysa Mineo | 女 | Director | 53 | 未披露 | 未持股 | 2018-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Daruwala | 男 | Chief Commercial Officer and Chief Operating Officer | 49 | 未披露 | 未持股 | 2018-04-27 |
| Matthew Onaitis | 男 | Chief Financial Officer and General Counsel | 47 | 100.18万美元 | 未持股 | 2018-04-27 |
| Taylor Sandison | 男 | VP-department | 46 | 99.93万美元 | 未持股 | 2018-04-27 |
| Neil Abdollahian | 男 | Chief Business Officer | 45 | 94.56万美元 | 未持股 | 2018-04-27 |
| Jeffrey Stein | 男 | Director,President and Chief Executive Officer | 63 | 182.38万美元 | 未持股 | 2018-04-27 |
董事简历
中英对照 | 中文 | 英文- Scott Rocklage
-
Scott Rocklage，2013年起，担任本公司董事。他于2003年加入风投公司5AM Ventures，担任风险合伙人；于2004年成为管理合伙人。加入5AM Ventures之前，1994-2003，他担任Cubist Pharmaceuticals Inc的首席执行官、董事长，这是上市的制药公司；1986-1989，担任诊断成像公司Nycomed Salutar, Inc的总裁、首席执行官。他还在私营制药公司Nycomed and Catalytica, Inc担任过多个研发职务。他目前是制药公司Novira, Inc.、生物可再生化学私营公司Rennovia, Inc、私营技术公司Kinestral Technologies的董事长。他还任职于下列董事会：Achaogen, Inc.，生物制药上市企业； Pulmatrix, Inc.， 生物技术私营企业；Epirus Biopharmaceuticals, Inc.， 生物制药上市企业。他在University of California, Berkeley获得化学学士学位，在Massachusetts Institute of Technology获得化学博士学位。
Scott Rocklage, Ph.D.,has served as a member of our Board since 2013. Dr. Rocklage joined 5AM Ventures, a venture capital firm, in 2003 as a Venture Partner and became a Managing Partner in 2004. Prior to joining 5AM Ventures, Dr. Rocklage served as Chief Executive Officer and Chairman of the Board of Cubist Pharmaceuticals Inc., a publicly-traded pharmaceutical company, from 1994 to 2003 and as President and Chief Executive Officer of Nycomed Salutar, Inc., a diagnostic imaging company, from 1986 to 1989. Dr. Rocklage has also served in various research and development positions at Nycomed and Catalytica, Inc., a private pharmaceutical company. Dr. Rocklage currently serves as the chairman of the board of directors of Rennovia, Inc., a private bio-renewable chemical company, Kinestral Technologies, a private technology company, Aprea Therapeutics, a private biopharmaceutical company, and Expansion Therapeutics, a private biopharmaceutical company. Dr. Rocklage previously served on the board of directors of Achaogen, Inc., Epirus Biopharmaceuticals, Inc., Relypsa, Inc., and VBI Vaccines, Inc., all public biopharmaceutical companies, and Pulmatrix, Inc., a public biotechnology company. Dr. Rocklage holds a B.S. in chemistry from the University of California, Berkeley and a Ph.D. in chemistry from the Massachusetts Institute of Technology. - Scott Rocklage，2013年起，担任本公司董事。他于2003年加入风投公司5AM Ventures，担任风险合伙人；于2004年成为管理合伙人。加入5AM Ventures之前，1994-2003，他担任Cubist Pharmaceuticals Inc的首席执行官、董事长，这是上市的制药公司；1986-1989，担任诊断成像公司Nycomed Salutar, Inc的总裁、首席执行官。他还在私营制药公司Nycomed and Catalytica, Inc担任过多个研发职务。他目前是制药公司Novira, Inc.、生物可再生化学私营公司Rennovia, Inc、私营技术公司Kinestral Technologies的董事长。他还任职于下列董事会：Achaogen, Inc.，生物制药上市企业； Pulmatrix, Inc.， 生物技术私营企业；Epirus Biopharmaceuticals, Inc.， 生物制药上市企业。他在University of California, Berkeley获得化学学士学位，在Massachusetts Institute of Technology获得化学博士学位。
- Scott Rocklage, Ph.D.,has served as a member of our Board since 2013. Dr. Rocklage joined 5AM Ventures, a venture capital firm, in 2003 as a Venture Partner and became a Managing Partner in 2004. Prior to joining 5AM Ventures, Dr. Rocklage served as Chief Executive Officer and Chairman of the Board of Cubist Pharmaceuticals Inc., a publicly-traded pharmaceutical company, from 1994 to 2003 and as President and Chief Executive Officer of Nycomed Salutar, Inc., a diagnostic imaging company, from 1986 to 1989. Dr. Rocklage has also served in various research and development positions at Nycomed and Catalytica, Inc., a private pharmaceutical company. Dr. Rocklage currently serves as the chairman of the board of directors of Rennovia, Inc., a private bio-renewable chemical company, Kinestral Technologies, a private technology company, Aprea Therapeutics, a private biopharmaceutical company, and Expansion Therapeutics, a private biopharmaceutical company. Dr. Rocklage previously served on the board of directors of Achaogen, Inc., Epirus Biopharmaceuticals, Inc., Relypsa, Inc., and VBI Vaccines, Inc., all public biopharmaceutical companies, and Pulmatrix, Inc., a public biotechnology company. Dr. Rocklage holds a B.S. in chemistry from the University of California, Berkeley and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
- Theodore R. Schroeder
-
Theodore R. Schroeder，2004年8月以来，一直担任本公司董事。他有着20多年的生命科学行业经验。最近，他是Cadence Pharmaceuticals的创始人，并自2004年成立之时起，担任其总裁、首席执行官，直到2014年它被Mallinckrodt收购。创办该公司之前，他在Elan Pharmaceuticals, Inc.担任了愈益重要的多个职务，其中包括北美销售与营销高级副总裁，副总裁、医院产品业务部总经理。此前，他曾担任Dura Pharmaceuticals, Inc.的急性护理营销高级总监，直到2001年它被Elan收购。加入Dura之前，他在Bristol-Myers Squibb Company担任过一些涉及医院的销售和营销职务。他现为Cidara Therapeutics的董事、薪酬委员会主席。此前，他曾担任Incline Therapeutics、Trius Therapeutics的董事，直到它们被收购。他是Sharp Hospital Foundation的委员会成员、Biocom的主席。他在Rutgers University获得管理学士学位。
Theodore R. Schroeder has served as a member of our Board since January 2016. Mr. Schroeder currently serves as Chief Executive Officer and as a member of the board of directors of Nabriva Therapeutics, Plc. “Nabriva”, a public biopharmaceutical company, a position he has held since July 2018. From June 2015 to July 2018 Mr. Schroeder was the President, CEO and member of the board of Zavante Therapeutics, a private biopharmaceutical company that he co-founded until its acquisition by Nabriva. Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc., a formerly public pharmaceutical company, and served as its President and Chief Executive Officer, and as a member of the board of directors, from May 2004 until its acquisition in May 2014 by Mallinckrodt Pharmaceuticals, Inc. From August 2002 to February 2004 Mr. Schroeder served as Senior Vice President, North American Sales and Marketing, of Elan Pharmaceuticals, Inc., a neuroscience-based pharmaceutical company, and from February 2001 to August 2002 as General Manager of the Hospital Products Business Unit. From May 1999 until its acquisition by Elan Pharmaceuticals, Inc. in November 2000 Mr. Schroeder served as Senior Director of Marketing Hospital Products at Dura Pharmaceuticals, Inc., a specialty respiratory pharmaceutical and pulmonary drug delivery company. Prior to joining Dura Pharmaceuticals, Inc., Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder currently serves on the board of directors of Cidara Therapeutics, Inc. (NASDAQ: CDTX) (2014 to present) and Otonomy Inc. (NASDAQ: OTIC) (August 2015 to present). From August 2011 until its acquisition by Horizon Pharma, Inc. in May 2015 Mr. Schroeder served on the board of directors of Hyperion Therapeutics, Inc., a formerly public company focused on treating ultra-rare diseases. From December 2009 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013 he served on the board of directors of Trius Therapeutics, Inc., a formerly public biopharmaceutical company. From June 2010 until its acquisition by the Medicines Company in January 2013 Mr. Schroeder served on the board of directors of Incline Therapeutics, a formerly private biopharmaceutical company focused in the acute pain space. Mr. Schroeder also currently serves on the board of directors of Biocom, a regional life science trade association, where he is a member of the executive committee. Mr. Schroeder received a B.S. in management from Rutgers University. - Theodore R. Schroeder，2004年8月以来，一直担任本公司董事。他有着20多年的生命科学行业经验。最近，他是Cadence Pharmaceuticals的创始人，并自2004年成立之时起，担任其总裁、首席执行官，直到2014年它被Mallinckrodt收购。创办该公司之前，他在Elan Pharmaceuticals, Inc.担任了愈益重要的多个职务，其中包括北美销售与营销高级副总裁，副总裁、医院产品业务部总经理。此前，他曾担任Dura Pharmaceuticals, Inc.的急性护理营销高级总监，直到2001年它被Elan收购。加入Dura之前，他在Bristol-Myers Squibb Company担任过一些涉及医院的销售和营销职务。他现为Cidara Therapeutics的董事、薪酬委员会主席。此前，他曾担任Incline Therapeutics、Trius Therapeutics的董事，直到它们被收购。他是Sharp Hospital Foundation的委员会成员、Biocom的主席。他在Rutgers University获得管理学士学位。
- Theodore R. Schroeder has served as a member of our Board since January 2016. Mr. Schroeder currently serves as Chief Executive Officer and as a member of the board of directors of Nabriva Therapeutics, Plc. “Nabriva”, a public biopharmaceutical company, a position he has held since July 2018. From June 2015 to July 2018 Mr. Schroeder was the President, CEO and member of the board of Zavante Therapeutics, a private biopharmaceutical company that he co-founded until its acquisition by Nabriva. Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc., a formerly public pharmaceutical company, and served as its President and Chief Executive Officer, and as a member of the board of directors, from May 2004 until its acquisition in May 2014 by Mallinckrodt Pharmaceuticals, Inc. From August 2002 to February 2004 Mr. Schroeder served as Senior Vice President, North American Sales and Marketing, of Elan Pharmaceuticals, Inc., a neuroscience-based pharmaceutical company, and from February 2001 to August 2002 as General Manager of the Hospital Products Business Unit. From May 1999 until its acquisition by Elan Pharmaceuticals, Inc. in November 2000 Mr. Schroeder served as Senior Director of Marketing Hospital Products at Dura Pharmaceuticals, Inc., a specialty respiratory pharmaceutical and pulmonary drug delivery company. Prior to joining Dura Pharmaceuticals, Inc., Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder currently serves on the board of directors of Cidara Therapeutics, Inc. (NASDAQ: CDTX) (2014 to present) and Otonomy Inc. (NASDAQ: OTIC) (August 2015 to present). From August 2011 until its acquisition by Horizon Pharma, Inc. in May 2015 Mr. Schroeder served on the board of directors of Hyperion Therapeutics, Inc., a formerly public company focused on treating ultra-rare diseases. From December 2009 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013 he served on the board of directors of Trius Therapeutics, Inc., a formerly public biopharmaceutical company. From June 2010 until its acquisition by the Medicines Company in January 2013 Mr. Schroeder served on the board of directors of Incline Therapeutics, a formerly private biopharmaceutical company focused in the acute pain space. Mr. Schroeder also currently serves on the board of directors of Biocom, a regional life science trade association, where he is a member of the executive committee. Mr. Schroeder received a B.S. in management from Rutgers University.
- Timothy R. Franson
-
Timothy R. Franson，曾在Paratek Pharmaceuticals, Inc.任职。自2015年7月起担任董事会成员。目前，他是健康和FDA实践部门Faegre Drinker咨询公司的负责人。2014年4月至2019年7月，他担任YourEncore的首席医疗官。直到2008年，他担任Lilly Research Laboratories（Eli Lilly and Company）的全球监管事务副总裁。他曾共同主持多个行业倡议的工作组，包括联合食品和药物管理局（FDA），1997年FDA现代化法案临床方面的行业工作组。2010年至2015年，他担任US Pharmacopeia Convention（USP）主席，该公约建立了由FDA等监管机构执行的药品质量标准，并在该组织的董事会担任前任主席，直到2020年。此外，他担任Cidara Therapeutics, Inc.的董事会成员。2016年至2021年，他担任Critical Path Institute（与FDA和行业合作推进创新）的董事会主席，并继续担任该董事会的前任主席。2010年至2013年，他还担任Myrexis, Inc.（前身为Myriad Pharmaceuticals, Inc.）的董事会成员。他在University of Illinois医学院获得医学学位，并获得内科和传染病委员会认证。
Timothy R. Franson,has served on Paratek Pharmaceuticals, Inc. Board since July 2015. Currently he is a Principal in Faegre Drinker Consulting in the Health and FDA Practice sectors. From April 2014 to July 2019, Dr. Franson served as the Chief Medical Officer for YourEncore. Until 2008, Dr. Franson was Vice President of Global Regulatory Affairs at Lilly Research Laboratories (Eli Lilly and Company). He has co-chaired working groups for several industry initiatives, including the joint Food and Drug Administration (FDA), industry working group addressing clinical aspects of the FDA Modernization Act of 1997. Dr. Franson served as the President of the US Pharmacopeia Convention (USP), which establishes drug quality standards enforced by regulators such as FDA, from 2010 to 2015, and served on the organization's Board of Trustees as immediate Past President until 2020. In addition, Dr. Franson serves as a member of the board of directors for Cidara Therapeutics, Inc. From 2016 to 2021, Dr. Franson served as Chair of the board of directors for the Critical Path Institute, which collaborates with FDA and industry in innovation advances, and remains on that board as Immediate Past Chair. He also served on the board of directors for Myrexis, Inc. (formerly Myriad Pharmaceuticals, Inc.) from 2010 to 2013. Dr. Franson received his medical degree from the University of Illinois College of Medicine and is Board certified in Internal Medicine and Infectious Disease. - Timothy R. Franson，曾在Paratek Pharmaceuticals, Inc.任职。自2015年7月起担任董事会成员。目前，他是健康和FDA实践部门Faegre Drinker咨询公司的负责人。2014年4月至2019年7月，他担任YourEncore的首席医疗官。直到2008年，他担任Lilly Research Laboratories（Eli Lilly and Company）的全球监管事务副总裁。他曾共同主持多个行业倡议的工作组，包括联合食品和药物管理局（FDA），1997年FDA现代化法案临床方面的行业工作组。2010年至2015年，他担任US Pharmacopeia Convention（USP）主席，该公约建立了由FDA等监管机构执行的药品质量标准，并在该组织的董事会担任前任主席，直到2020年。此外，他担任Cidara Therapeutics, Inc.的董事会成员。2016年至2021年，他担任Critical Path Institute（与FDA和行业合作推进创新）的董事会主席，并继续担任该董事会的前任主席。2010年至2013年，他还担任Myrexis, Inc.（前身为Myriad Pharmaceuticals, Inc.）的董事会成员。他在University of Illinois医学院获得医学学位，并获得内科和传染病委员会认证。
- Timothy R. Franson,has served on Paratek Pharmaceuticals, Inc. Board since July 2015. Currently he is a Principal in Faegre Drinker Consulting in the Health and FDA Practice sectors. From April 2014 to July 2019, Dr. Franson served as the Chief Medical Officer for YourEncore. Until 2008, Dr. Franson was Vice President of Global Regulatory Affairs at Lilly Research Laboratories (Eli Lilly and Company). He has co-chaired working groups for several industry initiatives, including the joint Food and Drug Administration (FDA), industry working group addressing clinical aspects of the FDA Modernization Act of 1997. Dr. Franson served as the President of the US Pharmacopeia Convention (USP), which establishes drug quality standards enforced by regulators such as FDA, from 2010 to 2015, and served on the organization's Board of Trustees as immediate Past President until 2020. In addition, Dr. Franson serves as a member of the board of directors for Cidara Therapeutics, Inc. From 2016 to 2021, Dr. Franson served as Chair of the board of directors for the Critical Path Institute, which collaborates with FDA and industry in innovation advances, and remains on that board as Immediate Past Chair. He also served on the board of directors for Myrexis, Inc. (formerly Myriad Pharmaceuticals, Inc.) from 2010 to 2013. Dr. Franson received his medical degree from the University of Illinois College of Medicine and is Board certified in Internal Medicine and Infectious Disease.
- Daniel D. Burgess
-
Daniel D. Burgess ，2014年4月以来，曾担任我们董事会的一员。Burgess先生目前是SV Life Sciences企业合伙人，该公司是一家投资基金，2014年6月以来，就一直担任该职位。从2011年6月直到2013年12月该公司被 The Medicines Company收购，他一直是 Rempex Pharmaceuticals, Inc.总裁兼首席执行官，该公司是一家私人生物制药公司。从2013年12月到2014年6月，他运营Rempex药品公司的子公司。在此之前，Burgess先生是Mpex Pharmaceuticals, Inc.的总裁兼首席执行官，该公司是一个私人生物制药公司，从2007年5月到2011年4月Aptalis制药公司收购该公司（现在的一个子公司），该公司是一家上市医药公司。从1999年8月到2007年5月，Burgess先生是Harbor BioSciences, Inc.（之前的Hollis-Eden Pharmaceuticals, Inc.）的首席运营官和首席财务官，该公司是一家制药公司。Burgess先生在加入 Harbor BioSciences之前，在Nanogen, Inc., Gensia Sicor, Inc., Castle & Cooke, Inc. 和 Smith Barney, Harris Upham 和 Company担任职位。从2004年3月到2010年1月该公司被Ligand Pharmaceuticals Incorporated收购，Burgess先生担任Metabasis Therapeutics, Inc.总裁。从2004年7月到2014年1月被Salix Pharmaceuticals, Inc.收购，Burgess先生在Santarus, Inc.董事会任职，该公司是一家上市生物制药公司。Burgess先生持有斯坦福大学经济学学士学位和哈佛商学院MBA学位。
Daniel D. Burgess,has served as a member of our Board since April 2014. Mr. Burgess is currently a venture partner at SV Health Investors, an investment fund, a position he has held since June 2014. From June 2011 until its acquisition by The Medicines Company in December 2013 he was the President and Chief Executive Officer of Rempex Pharmaceuticals, Inc., a private biopharmaceutical company. From December 2013 until June 2014 he ran the Rempex subsidiary of The Medicines Company. Prior to that, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., a private biopharmaceutical company, from May 2007 until its acquisition by Aptalis Pharma Inc., now a subsidiary of Allergan plc, a publicly-traded pharmaceutical company, in April 2011. Prior to joining Mpex, Mr. Burgess held positions at Hollis-Eden Pharmaceuticals, Inc., Nanogen, Inc., Gensia Sicor, Inc., Castle & Cooke, Inc. and Smith Barney, Harris Upham and Company. Mr. Burgess serves as a director of Arbutus Biopharma Corporation and chairman of the board of Nabriva Therapeutics plc, each of which is a publicly-traded pharmaceutical company, as well as a director of several private companies. From July 2004 until its acquisition by Salix Pharmaceuticals, Inc. in January 2014 Mr. Burgess served on the board of directors of Santarus, Inc., a publicly-traded biopharmaceutical company. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School. - Daniel D. Burgess ，2014年4月以来，曾担任我们董事会的一员。Burgess先生目前是SV Life Sciences企业合伙人，该公司是一家投资基金，2014年6月以来，就一直担任该职位。从2011年6月直到2013年12月该公司被 The Medicines Company收购，他一直是 Rempex Pharmaceuticals, Inc.总裁兼首席执行官，该公司是一家私人生物制药公司。从2013年12月到2014年6月，他运营Rempex药品公司的子公司。在此之前，Burgess先生是Mpex Pharmaceuticals, Inc.的总裁兼首席执行官，该公司是一个私人生物制药公司，从2007年5月到2011年4月Aptalis制药公司收购该公司（现在的一个子公司），该公司是一家上市医药公司。从1999年8月到2007年5月，Burgess先生是Harbor BioSciences, Inc.（之前的Hollis-Eden Pharmaceuticals, Inc.）的首席运营官和首席财务官，该公司是一家制药公司。Burgess先生在加入 Harbor BioSciences之前，在Nanogen, Inc., Gensia Sicor, Inc., Castle & Cooke, Inc. 和 Smith Barney, Harris Upham 和 Company担任职位。从2004年3月到2010年1月该公司被Ligand Pharmaceuticals Incorporated收购，Burgess先生担任Metabasis Therapeutics, Inc.总裁。从2004年7月到2014年1月被Salix Pharmaceuticals, Inc.收购，Burgess先生在Santarus, Inc.董事会任职，该公司是一家上市生物制药公司。Burgess先生持有斯坦福大学经济学学士学位和哈佛商学院MBA学位。
- Daniel D. Burgess,has served as a member of our Board since April 2014. Mr. Burgess is currently a venture partner at SV Health Investors, an investment fund, a position he has held since June 2014. From June 2011 until its acquisition by The Medicines Company in December 2013 he was the President and Chief Executive Officer of Rempex Pharmaceuticals, Inc., a private biopharmaceutical company. From December 2013 until June 2014 he ran the Rempex subsidiary of The Medicines Company. Prior to that, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., a private biopharmaceutical company, from May 2007 until its acquisition by Aptalis Pharma Inc., now a subsidiary of Allergan plc, a publicly-traded pharmaceutical company, in April 2011. Prior to joining Mpex, Mr. Burgess held positions at Hollis-Eden Pharmaceuticals, Inc., Nanogen, Inc., Gensia Sicor, Inc., Castle & Cooke, Inc. and Smith Barney, Harris Upham and Company. Mr. Burgess serves as a director of Arbutus Biopharma Corporation and chairman of the board of Nabriva Therapeutics plc, each of which is a publicly-traded pharmaceutical company, as well as a director of several private companies. From July 2004 until its acquisition by Salix Pharmaceuticals, Inc. in January 2014 Mr. Burgess served on the board of directors of Santarus, Inc., a publicly-traded biopharmaceutical company. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.
- Jeffrey Stein
-
Jeffrey Stein，自2014年起担任Cidara Therapeutics的总裁、首席执行官兼董事。在加入Cidara之前，他自2007年Trius Therapeutics成立起担任其首席执行官，直至2013年9月被Cubist Pharmaceuticals收购。他也是the Antibiotics Working Group（行业领导501c（6）组织）的创始董事长兼总裁。此前，他是Sofinnova Ventures的风险合伙人兼Kauffman研究员，并于2005年成立圣地亚哥办公室。在加入Sofinnova之前，他是Quorex Pharmaceuticals（2005年被Pfizer Pharmaceuticals收购）的联合创始人兼首席科学官。他也是Diversa Corporation和the Agouron Institute的首席科学家。他作为一名Alexander Hollaender Distinguished Postdoctoral研究员在the California Institute of Technology进行博士后研究，并以NASA Graduate Student Researcher Fellow身份在U.C.S.D。进行研究生工作。
Jeffrey Stein,has served on Paratek Pharmaceuticals, Inc. Board since October 2014 and was appointed as Paratek Pharmaceuticals, Inc. Lead Independent Director in December 2022. Dr. Stein has been the President, Chief Executive Officer and Director of Cidara Therapeutics, Inc., or Cidara, since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics, Inc. from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September 2013. Dr. Stein is also founding Chairman and President of the Antibiotics Working Group, an industry leading 501(c)(6) organization. In addition to serving on the boards of Cidara and Paratek, Dr. Stein is currently a director of Ideaya Biosciences, Inc. and serves on the board of managers of Life Science Cares, San Diego. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, Inc. which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego. - Jeffrey Stein，自2014年起担任Cidara Therapeutics的总裁、首席执行官兼董事。在加入Cidara之前，他自2007年Trius Therapeutics成立起担任其首席执行官，直至2013年9月被Cubist Pharmaceuticals收购。他也是the Antibiotics Working Group（行业领导501c（6）组织）的创始董事长兼总裁。此前，他是Sofinnova Ventures的风险合伙人兼Kauffman研究员，并于2005年成立圣地亚哥办公室。在加入Sofinnova之前，他是Quorex Pharmaceuticals（2005年被Pfizer Pharmaceuticals收购）的联合创始人兼首席科学官。他也是Diversa Corporation和the Agouron Institute的首席科学家。他作为一名Alexander Hollaender Distinguished Postdoctoral研究员在the California Institute of Technology进行博士后研究，并以NASA Graduate Student Researcher Fellow身份在U.C.S.D。进行研究生工作。
- Jeffrey Stein,has served on Paratek Pharmaceuticals, Inc. Board since October 2014 and was appointed as Paratek Pharmaceuticals, Inc. Lead Independent Director in December 2022. Dr. Stein has been the President, Chief Executive Officer and Director of Cidara Therapeutics, Inc., or Cidara, since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics, Inc. from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September 2013. Dr. Stein is also founding Chairman and President of the Antibiotics Working Group, an industry leading 501(c)(6) organization. In addition to serving on the boards of Cidara and Paratek, Dr. Stein is currently a director of Ideaya Biosciences, Inc. and serves on the board of managers of Life Science Cares, San Diego. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, Inc. which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.
- Chrysa Mineo
-
Chrysa Mineo，2014年1月1日，她担任公司发展高级副总裁，2009年7月起，担任我公司公司发展副总裁。她负责我公司与AbbVie, Ono and Lilly的合作，以及与Janssen Pharmaceuticals的合作关系。她在生物技术业有23年的经历，包括1997至2009年担任Neurocrine Biosciences商业发展高级董事。加入Neurocrine之前，她在Amgen, DNAX Research Institute, Schering Plough和Baxter Biotech的研究、营销和商业发展担任多职。1987年，她在Amgen开始职业生涯，担任细胞生物小组成员。她在加利福尼亚大学戴维斯分校（University of California, Davis）获得动物学学士学位，在杜克大学福库商学院（Duke University’s Fuqua School of Business）获得工商管理学硕士学位。
Chrysa Mineo,has served as a member of our Board since March 2018. From 2009 to 2015 Ms. Mineo led corporate development at Receptos, Inc., a biotechnology company acquired by Celgene in 2015. Prior to Receptos, from 1997 to 2009 Ms. Mineo held roles of increasing business development responsibility at Neurocrine Biosciences, a biotechnology company. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen, DNAX Research Institute, Schering Plough and Baxter Biotech. Ms. Mineo holds a B.S. in Zoology from the University of California, Davis and an M.B.A. from Duke University’s Fuqua School of Business. - Chrysa Mineo，2014年1月1日，她担任公司发展高级副总裁，2009年7月起，担任我公司公司发展副总裁。她负责我公司与AbbVie, Ono and Lilly的合作，以及与Janssen Pharmaceuticals的合作关系。她在生物技术业有23年的经历，包括1997至2009年担任Neurocrine Biosciences商业发展高级董事。加入Neurocrine之前，她在Amgen, DNAX Research Institute, Schering Plough和Baxter Biotech的研究、营销和商业发展担任多职。1987年，她在Amgen开始职业生涯，担任细胞生物小组成员。她在加利福尼亚大学戴维斯分校（University of California, Davis）获得动物学学士学位，在杜克大学福库商学院（Duke University’s Fuqua School of Business）获得工商管理学硕士学位。
- Chrysa Mineo,has served as a member of our Board since March 2018. From 2009 to 2015 Ms. Mineo led corporate development at Receptos, Inc., a biotechnology company acquired by Celgene in 2015. Prior to Receptos, from 1997 to 2009 Ms. Mineo held roles of increasing business development responsibility at Neurocrine Biosciences, a biotechnology company. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen, DNAX Research Institute, Schering Plough and Baxter Biotech. Ms. Mineo holds a B.S. in Zoology from the University of California, Davis and an M.B.A. from Duke University’s Fuqua School of Business.
高管简历
中英对照 | 中文 | 英文- Paul Daruwala
Paul Daruwala，2014年12月加入本公司，担任首席商业官。2012年9月至2014年10月，他在Bristol-Myers Squibb Company担任美国病毒性肝炎特许经营HCV、HBV的副总裁，这是一个上市的制药公司。加入Bristol-Myers Squibb Company之前，他曾在2012年创办私营的咨询公司Delta Sage。2010年5月至2012年2月，他在Vertex Pharmaceuticals担任HCV商业与战略管理副总裁，负责治疗领域的战略、市场营销、病人服务，以及全国性的医疗护理支持团队。1992年至2010年5月，他在Merck & Co。担任过一些职务，包括：HCV美国负责人、抗病毒新产品全球负责人、医院抗菌专营业务全球负责人，以及 抗炎镇痛特许经营业务的营销与战略规划总监。他从事过几年的业务开发工作，领导商业和战略评估团队，最终使肿瘤、感染性疾病、免疫、代谢性疾病的相关工作通过临床前的第二阶段。职业生涯之初，他在Merck的美国部门从事销售、销售管理、市场管理。他在The University of Kentucky获得药物学学位。
Paul Daruwala,joined us as Chief Commercial Officer in December 2014 and became our Chief Operating Officer in January 2018. From September 2012 to October 2014 he was the Vice President of the U.S. Viral Hepatitis Franchise HCV and HBV at Bristol-Myers Squibb Company, a global pharmaceutical company. Before joining Bristol-Myers Squibb, Mr. Daruwala founded Delta Sage, a private consulting practice, in February 2012. From May 2010 to February 2012 Mr. Daruwala served as Vice President of Commercial and Strategic Management for HCV at Vertex Pharmaceuticals Incorporated, a biotechnology company, where he was responsible for the therapeutic area strategy, marketing, patient services, and a national field team of health care provider support. From 1992 to May 2010 Mr. Daruwala served in a number of roles at Merck & Co., a global pharmaceutical company, including: the U.S. lead for HCV, Global Lead for Antiviral New Products, Global Lead for the Hospital Antifungal Franchise, and Director of Marketing and Strategic Planning for the Anti-inflammatory and Analgesic Franchise. Mr. Daruwala spent several years in a business development role, leading commercial and strategic assessments which culminated in preclinical through Phase 2 transactions in oncology, infectious diseases, immunology, and metabolic diseases. He started his career in sales, sales management, and managed markets in Merck’s U.S. division. Mr. Daruwala received his degree in pharmacy from The University of Kentucky.- Paul Daruwala，2014年12月加入本公司，担任首席商业官。2012年9月至2014年10月，他在Bristol-Myers Squibb Company担任美国病毒性肝炎特许经营HCV、HBV的副总裁，这是一个上市的制药公司。加入Bristol-Myers Squibb Company之前，他曾在2012年创办私营的咨询公司Delta Sage。2010年5月至2012年2月，他在Vertex Pharmaceuticals担任HCV商业与战略管理副总裁，负责治疗领域的战略、市场营销、病人服务，以及全国性的医疗护理支持团队。1992年至2010年5月，他在Merck & Co。担任过一些职务，包括：HCV美国负责人、抗病毒新产品全球负责人、医院抗菌专营业务全球负责人，以及 抗炎镇痛特许经营业务的营销与战略规划总监。他从事过几年的业务开发工作，领导商业和战略评估团队，最终使肿瘤、感染性疾病、免疫、代谢性疾病的相关工作通过临床前的第二阶段。职业生涯之初，他在Merck的美国部门从事销售、销售管理、市场管理。他在The University of Kentucky获得药物学学位。
- Paul Daruwala,joined us as Chief Commercial Officer in December 2014 and became our Chief Operating Officer in January 2018. From September 2012 to October 2014 he was the Vice President of the U.S. Viral Hepatitis Franchise HCV and HBV at Bristol-Myers Squibb Company, a global pharmaceutical company. Before joining Bristol-Myers Squibb, Mr. Daruwala founded Delta Sage, a private consulting practice, in February 2012. From May 2010 to February 2012 Mr. Daruwala served as Vice President of Commercial and Strategic Management for HCV at Vertex Pharmaceuticals Incorporated, a biotechnology company, where he was responsible for the therapeutic area strategy, marketing, patient services, and a national field team of health care provider support. From 1992 to May 2010 Mr. Daruwala served in a number of roles at Merck & Co., a global pharmaceutical company, including: the U.S. lead for HCV, Global Lead for Antiviral New Products, Global Lead for the Hospital Antifungal Franchise, and Director of Marketing and Strategic Planning for the Anti-inflammatory and Analgesic Franchise. Mr. Daruwala spent several years in a business development role, leading commercial and strategic assessments which culminated in preclinical through Phase 2 transactions in oncology, infectious diseases, immunology, and metabolic diseases. He started his career in sales, sales management, and managed markets in Merck’s U.S. division. Mr. Daruwala received his degree in pharmacy from The University of Kentucky.
- Matthew Onaitis
Matthew Onaitis，于2016年7月加入我们，担任首席财务官and General Counsel。此前，奥奈蒂斯曾于2014年2月至2016年6月担任上市生物制药公司Ignyta，Inc.的总法律顾问兼秘书，TriusTherapeutics，Inc.是一家上市生物制药公司，从2013年5月开始，通过2013年9月被Cubist Pharmaceuticals收购，继续留在Cubist，并协助整合到2013年12月。从2006年5月到2013年3月Pernix TherapeuticsHoldings，Inc.收购Somaxon，Onaitis先生担任SomaxonPharmaceuticals，Inc.（一家公开上市的制药公司）的高级副总裁，总法律顾问兼秘书。在加入Somaxon之前，Onaitis先生担任Biogen Idec Inc.（一家全球生物技术公司）的副总法律顾问，担任Elan Corporation plc（一家全球生物技术公司）的法律事务总监，并从事私人执业，专门从事公司法和商业法。Onaitis先生是Stratify Genomics Inc.的董事。Onaitis先生拥有Stanford Law School的法学博士学位和Carnegie Mellon University的机械工程学士学位。
Matthew Onaitis,joined us as Chief Financial Officer and General Counsel in July 2016. Previously, Mr. Onaitis served as General Counsel and Secretary of Ignyta, Inc., a publicly-traded biopharmaceutical company, from February 2014 through June 2016 and General Counsel of Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, beginning in May 2013 through its acquisition by Cubist Pharmaceuticals in September 2013 remaining with Cubist and assisting with the integration through December 2013. Mr. Onaitis was Senior Vice President, General Counsel and Secretary at Somaxon Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, from May 2006 through Somaxon’s acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Prior to Somaxon, Mr. Onaitis served as Associate General Counsel at Biogen Idec Inc., a global biotechnology company, as Director, Legal Affairs at Elan Corporation plc, a global biotechnology company, and in private practice specializing in corporate and commercial law. Mr. Onaitis is a director of Stratify Genomics Inc. Mr. Onaitis holds a J.D. from Stanford Law School and a B.S. in mechanical engineering from Carnegie Mellon University.- Matthew Onaitis，于2016年7月加入我们，担任首席财务官and General Counsel。此前，奥奈蒂斯曾于2014年2月至2016年6月担任上市生物制药公司Ignyta，Inc.的总法律顾问兼秘书，TriusTherapeutics，Inc.是一家上市生物制药公司，从2013年5月开始，通过2013年9月被Cubist Pharmaceuticals收购，继续留在Cubist，并协助整合到2013年12月。从2006年5月到2013年3月Pernix TherapeuticsHoldings，Inc.收购Somaxon，Onaitis先生担任SomaxonPharmaceuticals，Inc.（一家公开上市的制药公司）的高级副总裁，总法律顾问兼秘书。在加入Somaxon之前，Onaitis先生担任Biogen Idec Inc.（一家全球生物技术公司）的副总法律顾问，担任Elan Corporation plc（一家全球生物技术公司）的法律事务总监，并从事私人执业，专门从事公司法和商业法。Onaitis先生是Stratify Genomics Inc.的董事。Onaitis先生拥有Stanford Law School的法学博士学位和Carnegie Mellon University的机械工程学士学位。
- Matthew Onaitis,joined us as Chief Financial Officer and General Counsel in July 2016. Previously, Mr. Onaitis served as General Counsel and Secretary of Ignyta, Inc., a publicly-traded biopharmaceutical company, from February 2014 through June 2016 and General Counsel of Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, beginning in May 2013 through its acquisition by Cubist Pharmaceuticals in September 2013 remaining with Cubist and assisting with the integration through December 2013. Mr. Onaitis was Senior Vice President, General Counsel and Secretary at Somaxon Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, from May 2006 through Somaxon’s acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Prior to Somaxon, Mr. Onaitis served as Associate General Counsel at Biogen Idec Inc., a global biotechnology company, as Director, Legal Affairs at Elan Corporation plc, a global biotechnology company, and in private practice specializing in corporate and commercial law. Mr. Onaitis is a director of Stratify Genomics Inc. Mr. Onaitis holds a J.D. from Stanford Law School and a B.S. in mechanical engineering from Carnegie Mellon University.
- Taylor Sandison
Taylor Sandison，医学博士，自2015年10月起在Cidara任职。在加入公司之前，他在默克公司担任高级医疗主任，在此之前，他在CubistPharmaceuticals，Inc.公司担任同样的职务Sandison博士还曾在上市生物制药公司TriusTherapeutics，Inc.和Novartis Diagnostics任职，并担任斯坦福大学和华盛顿大学医学系教员。他在达特茅斯学院（Dartmouth College）获得B.S.和B.A.学位，在华盛顿大学（University of Washington）获得M.D.和M.P.H.学位，在伦敦卫生与热带医学院（London School of Hygiene and Tropical Medicine）获得热带医学与卫生DTM&H文凭。他在科罗拉多大学（University of Colorado）完成内科住院医师培训，在华盛顿大学（University of Washington）完成传染病奖学金培训。Sandison博士目前持有传染病和内科的董事会认证。
Taylor Sandison, M.D.,has been with Cidara since October 2015. Prior to joining the company, he served as senior medical director at Merck and prior to that held the same position at Cubist Pharmaceuticals, Inc. Dr. Sandison has also held positions at Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, and Novartis Diagnostics, and served as a member of the faculty in the Department of Medicine at both Stanford University and the University of Washington. He received B.S. and B.A. degrees from Dartmouth College, M.D. and M.P.H. degrees from the University of Washington, and a Diploma in Tropical Medicine and Hygiene DTM&H from the London School of Hygiene and Tropical Medicine. He completed internal medicine residency training at the University of Colorado and infectious diseases fellowship training at the University of Washington. Dr. Sandison currently holds board certifications in Infectious Diseases and Internal Medicine.- Taylor Sandison，医学博士，自2015年10月起在Cidara任职。在加入公司之前，他在默克公司担任高级医疗主任，在此之前，他在CubistPharmaceuticals，Inc.公司担任同样的职务Sandison博士还曾在上市生物制药公司TriusTherapeutics，Inc.和Novartis Diagnostics任职，并担任斯坦福大学和华盛顿大学医学系教员。他在达特茅斯学院（Dartmouth College）获得B.S.和B.A.学位，在华盛顿大学（University of Washington）获得M.D.和M.P.H.学位，在伦敦卫生与热带医学院（London School of Hygiene and Tropical Medicine）获得热带医学与卫生DTM&H文凭。他在科罗拉多大学（University of Colorado）完成内科住院医师培训，在华盛顿大学（University of Washington）完成传染病奖学金培训。Sandison博士目前持有传染病和内科的董事会认证。
- Taylor Sandison, M.D.,has been with Cidara since October 2015. Prior to joining the company, he served as senior medical director at Merck and prior to that held the same position at Cubist Pharmaceuticals, Inc. Dr. Sandison has also held positions at Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, and Novartis Diagnostics, and served as a member of the faculty in the Department of Medicine at both Stanford University and the University of Washington. He received B.S. and B.A. degrees from Dartmouth College, M.D. and M.P.H. degrees from the University of Washington, and a Diploma in Tropical Medicine and Hygiene DTM&H from the London School of Hygiene and Tropical Medicine. He completed internal medicine residency training at the University of Colorado and infectious diseases fellowship training at the University of Washington. Dr. Sandison currently holds board certifications in Infectious Diseases and Internal Medicine.
- Neil Abdollahian
Neil Abdollahian，自2021年8月起担任Boundless Bio，Inc.首席商务官。在加入Boundless之前，Abdollahian先生于2016年7月至2021年8月期间担任上市生物制药公司Cidara Therapeutics, Inc.的首席商务官。在加入Cidara之前，Abdollahian先生是Clarity Point Partners，LLC的董事总经理，该公司是一家战略咨询公司，专注于企业发展计划，包括生物制药产品收购和许可。在此之前，Abdollahian先生曾担任过各种领导职务，包括在TRIUS治疗担任业务发展副总裁，在那里他领导了导致被Cubist Pharmaceuticals收购的努力。Abdollahian先生还曾在Emerging Growth Capital Pty、Avanir制药和Isis Pharmaceuticals担任过更早的各种业务和企业发展职务。Abdollahian获得了乔治华盛顿大学的生物学学士学位、新墨西哥大学医学院的生物医学科学硕士学位以及佩珀代因大学的MBA学位。
Neil Abdollahian,has served as Boundless Bio, Inc. Chief Business Officer since August 2021. Prior to Boundless, Mr. Abdollahian served as Chief Business Officer of Cidara Therapeutics, Inc., a publicly traded biopharmaceutical company, from July 2016 to August 2021. Prior to Cidara, Mr. Abdollahian was Managing Director of Clarity Point Partners, LLC, a strategic advisory firm focused on corporate development initiatives including biopharmaceutical product acquisitions and licensing. Previously, Mr. Abdollahian served in various leadership roles including Vice President of Business Development at Trius Therapeutics, Inc., where he led the efforts resulting in the acquisition by Cubist Pharmaceuticals. Mr. Abdollahian also served earlier in various business and corporate development roles at Emerging Growth Capital Pty, Avanir Pharmaceuticals, and Isis Pharmaceuticals.Mr. Abdollahian received a B.S in Biology from the George Washington University, a M.S. in Biomedical Sciences from University of New Mexico Medical School, and an MBA from Pepperdine University.- Neil Abdollahian，自2021年8月起担任Boundless Bio，Inc.首席商务官。在加入Boundless之前，Abdollahian先生于2016年7月至2021年8月期间担任上市生物制药公司Cidara Therapeutics, Inc.的首席商务官。在加入Cidara之前，Abdollahian先生是Clarity Point Partners，LLC的董事总经理，该公司是一家战略咨询公司，专注于企业发展计划，包括生物制药产品收购和许可。在此之前，Abdollahian先生曾担任过各种领导职务，包括在TRIUS治疗担任业务发展副总裁，在那里他领导了导致被Cubist Pharmaceuticals收购的努力。Abdollahian先生还曾在Emerging Growth Capital Pty、Avanir制药和Isis Pharmaceuticals担任过更早的各种业务和企业发展职务。Abdollahian获得了乔治华盛顿大学的生物学学士学位、新墨西哥大学医学院的生物医学科学硕士学位以及佩珀代因大学的MBA学位。
- Neil Abdollahian,has served as Boundless Bio, Inc. Chief Business Officer since August 2021. Prior to Boundless, Mr. Abdollahian served as Chief Business Officer of Cidara Therapeutics, Inc., a publicly traded biopharmaceutical company, from July 2016 to August 2021. Prior to Cidara, Mr. Abdollahian was Managing Director of Clarity Point Partners, LLC, a strategic advisory firm focused on corporate development initiatives including biopharmaceutical product acquisitions and licensing. Previously, Mr. Abdollahian served in various leadership roles including Vice President of Business Development at Trius Therapeutics, Inc., where he led the efforts resulting in the acquisition by Cubist Pharmaceuticals. Mr. Abdollahian also served earlier in various business and corporate development roles at Emerging Growth Capital Pty, Avanir Pharmaceuticals, and Isis Pharmaceuticals.Mr. Abdollahian received a B.S in Biology from the George Washington University, a M.S. in Biomedical Sciences from University of New Mexico Medical School, and an MBA from Pepperdine University.
- Jeffrey Stein
Jeffrey Stein，自2014年起担任Cidara Therapeutics的总裁、首席执行官兼董事。在加入Cidara之前，他自2007年Trius Therapeutics成立起担任其首席执行官，直至2013年9月被Cubist Pharmaceuticals收购。他也是the Antibiotics Working Group（行业领导501c（6）组织）的创始董事长兼总裁。此前，他是Sofinnova Ventures的风险合伙人兼Kauffman研究员，并于2005年成立圣地亚哥办公室。在加入Sofinnova之前，他是Quorex Pharmaceuticals（2005年被Pfizer Pharmaceuticals收购）的联合创始人兼首席科学官。他也是Diversa Corporation和the Agouron Institute的首席科学家。他作为一名Alexander Hollaender Distinguished Postdoctoral研究员在the California Institute of Technology进行博士后研究，并以NASA Graduate Student Researcher Fellow身份在U.C.S.D。进行研究生工作。
Jeffrey Stein,has served on Paratek Pharmaceuticals, Inc. Board since October 2014 and was appointed as Paratek Pharmaceuticals, Inc. Lead Independent Director in December 2022. Dr. Stein has been the President, Chief Executive Officer and Director of Cidara Therapeutics, Inc., or Cidara, since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics, Inc. from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September 2013. Dr. Stein is also founding Chairman and President of the Antibiotics Working Group, an industry leading 501(c)(6) organization. In addition to serving on the boards of Cidara and Paratek, Dr. Stein is currently a director of Ideaya Biosciences, Inc. and serves on the board of managers of Life Science Cares, San Diego. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, Inc. which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.- Jeffrey Stein，自2014年起担任Cidara Therapeutics的总裁、首席执行官兼董事。在加入Cidara之前，他自2007年Trius Therapeutics成立起担任其首席执行官，直至2013年9月被Cubist Pharmaceuticals收购。他也是the Antibiotics Working Group（行业领导501c（6）组织）的创始董事长兼总裁。此前，他是Sofinnova Ventures的风险合伙人兼Kauffman研究员，并于2005年成立圣地亚哥办公室。在加入Sofinnova之前，他是Quorex Pharmaceuticals（2005年被Pfizer Pharmaceuticals收购）的联合创始人兼首席科学官。他也是Diversa Corporation和the Agouron Institute的首席科学家。他作为一名Alexander Hollaender Distinguished Postdoctoral研究员在the California Institute of Technology进行博士后研究，并以NASA Graduate Student Researcher Fellow身份在U.C.S.D。进行研究生工作。
- Jeffrey Stein,has served on Paratek Pharmaceuticals, Inc. Board since October 2014 and was appointed as Paratek Pharmaceuticals, Inc. Lead Independent Director in December 2022. Dr. Stein has been the President, Chief Executive Officer and Director of Cidara Therapeutics, Inc., or Cidara, since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics, Inc. from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September 2013. Dr. Stein is also founding Chairman and President of the Antibiotics Working Group, an industry leading 501(c)(6) organization. In addition to serving on the boards of Cidara and Paratek, Dr. Stein is currently a director of Ideaya Biosciences, Inc. and serves on the board of managers of Life Science Cares, San Diego. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, Inc. which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.